Core Insights - The FISH&CHIPS study confirms total plaque volume (TPV) as a significant independent predictor of long-term cardiovascular events, enhancing the understanding of coronary artery disease (CAD) management through AI technology [1][2][7] Company Overview - Heartflow, Inc. is a leader in AI technology for CAD, with its Heartflow Plaque Analysis and Plaque Staging framework being the most clinically validated for actionable CAD care [1][4] - The company has been adopted by over 1,400 institutions globally and has supported nearly 500,000 patients, backed by ACC/AHA guidelines and over 600 peer-reviewed publications [4][9] Study Findings - The retrospective analysis involved nearly 8,000 symptomatic patients, marking the largest validation of the Heartflow Plaque Staging framework based on TPV measurement [2] - Key findings indicate that patients in the highest TPV stage have over a 5x greater risk of major cardiovascular events compared to those in the lowest stage, with a hazard ratio of 5.10 [7] - The study suggests that accurate plaque measurement can help cardiologists personalize treatment, potentially preventing future heart attacks or deaths [2][3] Clinical Impact - Changes in medical management guided by Heartflow Plaque Staging resulted in an average reduction of LDL cholesterol by 18.7 mg/dL at 90 days, indicating a 15% decrease in the risk of cardiac events [2] - Heartflow's AI-driven solutions have been validated through over 100 studies involving more than 365,000 patients, demonstrating high accuracy and reproducibility in clinical practice [8]

Core Insights - Heartflow, Inc. has presented new data from the FISH&CHIPS Study at the AHA Scientific Sessions 2025, reinforcing the effectiveness of its AI-powered Heartflow Plaque Analysis and Plaque Staging framework for coronary artery disease (CAD) [1][2] Group 1: Study Findings - The retrospective analysis involved nearly 8,000 symptomatic patients, marking the largest validation of the Heartflow Plaque Staging framework based on total plaque volume (TPV) measurement [2] - The study indicates that TPV-based staging is a strong predictor of future heart attacks or cardiovascular death, allowing for personalized treatment to prevent adverse outcomes [2][4] - Patients in the highest TPV stage faced over a 5x greater risk of major cardiovascular events compared to those in the lowest stage, with a hazard ratio of 5.10 [4] Group 2: Clinical Impact - The DECIDE Registry data showed that Heartflow Plaque Analysis with Plaque Staging led to changes in medical management for over 50% of patients, resulting in an average LDL cholesterol reduction of 18.7 mg/dL at 90 days [2] - Management changes guided by Heartflow Plaque Staging are expected to result in a 15% decrease in the risk of cardiac events [2] Group 3: Technology and Adoption - Heartflow's technology is redefining precision cardiovascular care through clinically-proven AI and a large coronary imaging dataset, adopted by over 1,400 institutions globally [3][5] - The company has validated its AI-driven solutions through over 100 studies involving more than 365,000 patients, achieving a coronary CTA image acceptance rate exceeding 96% [5] Group 4: Regulatory and Compliance - Heartflow's quality system meets or exceeds international standards, including HITRUST, SOC 2 Type 2, GDPR, HIPAA, CCPA, ISO 13485, and ISO 27001, ensuring patient data integrity and security [6]